Disease

Brain Cancer

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 9, 2026 · PHASE 2 TRIAL

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

ClinicalTrials.gov

This is an active Phase 2 interventional trial with no results posted; the registry record describes planned enrollment and primary outcome measures only, representing early-stage evaluation of a novel radiosensitizer in brain metastases.

PreliminaryBrain Cancer AGuIX gadolinium-based nanoparticles NCT04899908

Reported

Planned enrollment134

Study phasePhase 2

Primary outcome measureLocal Recurrence, assessed from enrollment…

AUG 10, 2026 · JOURNAL ARTICLE

Pathway dysregulation and therapeutic resistance in glioblastoma: molecular mechanisms and emerging therapeutic targets.

Future Science Oa

A narrative review synthesizing molecular mechanisms of glioblastoma resistance and recommending future therapeutic strategies, without new empirical data or clinical trial results.

Expert GuidanceBrain Cancer Targeted Therapy Jia Ming Chen

Study details

DesignNarrative review